208 related articles for article (PubMed ID: 29285650)
41. Gemigliptin exerts protective effects against doxorubicin-induced hepatotoxicity by inhibiting apoptosis via the regulation of fibroblast growth factor 21 expression.
Lee KM; Hwang YJ; Jung GS
Biochem Biophys Res Commun; 2022 Oct; 626():135-141. PubMed ID: 36049375
[TBL] [Abstract][Full Text] [Related]
42. Low concentration of metformin induces a p53-dependent senescence in hepatoma cells via activation of the AMPK pathway.
Yi G; He Z; Zhou X; Xian L; Yuan T; Jia X; Hong J; He L; Liu J
Int J Oncol; 2013 Nov; 43(5):1503-10. PubMed ID: 23982736
[TBL] [Abstract][Full Text] [Related]
43. Gemigliptin Inhibits Interleukin-1β-Induced Endothelial-Mesenchymal Transition via Canonical-Bone Morphogenetic Protein Pathway.
Hong OK; Lee SS; Yoo SJ; Lee MK; Kim MK; Baek KH; Song KH; Kwon HS
Endocrinol Metab (Seoul); 2020 Jun; 35(2):384-395. PubMed ID: 32615723
[TBL] [Abstract][Full Text] [Related]
44. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth.
Rocha GZ; Dias MM; Ropelle ER; Osório-Costa F; Rossato FA; Vercesi AE; Saad MJ; Carvalheira JB
Clin Cancer Res; 2011 Jun; 17(12):3993-4005. PubMed ID: 21543517
[TBL] [Abstract][Full Text] [Related]
45. Gemigliptin suppresses salivary dysfunction in streptozotocin-induced diabetic rats.
Kang WS; Jung WK; Park SB; Kim HR; Kim J
Biomed Pharmacother; 2021 May; 137():111297. PubMed ID: 33493968
[TBL] [Abstract][Full Text] [Related]
46. Differences in p53 status significantly influence the cellular response and cell survival to 1,25-dihydroxyvitamin D3-metformin cotreatment in colorectal cancer cells.
Abu El Maaty MA; Strassburger W; Qaiser T; Dabiri Y; Wölfl S
Mol Carcinog; 2017 Nov; 56(11):2486-2498. PubMed ID: 28618116
[TBL] [Abstract][Full Text] [Related]
47. Epigallocatechin gallate inhibits growth and epithelial-to-mesenchymal transition in human thyroid carcinoma cell lines.
De Amicis F; Perri A; Vizza D; Russo A; Panno ML; Bonofiglio D; Giordano C; Mauro L; Aquila S; Tramontano D; Andò S
J Cell Physiol; 2013 Oct; 228(10):2054-62. PubMed ID: 23553645
[TBL] [Abstract][Full Text] [Related]
48. Pharmacokinetic comparison of gemigliptin 50 mg and metformin 500 mg as a fixed-dose combination and loose combination
.
Lee SW; Park SI; Lee S; Chung JY; Yu KS
Int J Clin Pharmacol Ther; 2019 Feb; 57(2):117-124. PubMed ID: 30574864
[TBL] [Abstract][Full Text] [Related]
49. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
[TBL] [Abstract][Full Text] [Related]
50. Metformin inhibits thyroid cancer cell growth, migration, and EMT through the mTOR pathway.
Han B; Cui H; Kang L; Zhang X; Jin Z; Lu L; Fan Z
Tumour Biol; 2015 Aug; 36(8):6295-304. PubMed ID: 25854169
[TBL] [Abstract][Full Text] [Related]
51. Antidiabetic effect of gemigliptin: a systematic review and meta-analysis of randomized controlled trials with Bayesian inference through a quality management system.
Oh H; Nguyen HD; Yoon IM; Ahn BR; Kim MS
Sci Rep; 2021 Oct; 11(1):20938. PubMed ID: 34686738
[TBL] [Abstract][Full Text] [Related]
52. In vitro and in vivo anti-melanoma action of metformin.
Janjetovic K; Harhaji-Trajkovic L; Misirkic-Marjanovic M; Vucicevic L; Stevanovic D; Zogovic N; Sumarac-Dumanovic M; Micic D; Trajkovic V
Eur J Pharmacol; 2011 Oct; 668(3):373-82. PubMed ID: 21806981
[TBL] [Abstract][Full Text] [Related]
53. [The mechanism of aspirin combined with metformin induced apoptosis of thyroid cancer TPC-1 cells].
Qi L; Ye JW; Xue WH; Tian X; Zhang HJ
Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):276-281. PubMed ID: 31014052
[No Abstract] [Full Text] [Related]
54. Metformin-induced activation of AMPK inhibits the proliferation and migration of human aortic smooth muscle cells through upregulation of p53 and IFI16.
Hao B; Xiao Y; Song F; Long X; Huang J; Tian M; Deng S; Wu Q
Int J Mol Med; 2018 Mar; 41(3):1365-1376. PubMed ID: 29286156
[TBL] [Abstract][Full Text] [Related]
55. High efficacy of intravesical treatment of metformin on bladder cancer in preclinical model.
Peng M; Su Q; Zeng Q; Li L; Liu Z; Xue L; Cheng Y; Huang Y; Tao T; Lv H; Li X; Tao X; Guo P; Chen AF; Yang X
Oncotarget; 2016 Feb; 7(8):9102-17. PubMed ID: 26802022
[TBL] [Abstract][Full Text] [Related]
56. Inhibition of p38 MAPK-dependent MutS homologue-2 (MSH2) expression by metformin enhances gefitinib-induced cytotoxicity in human squamous lung cancer cells.
Ko JC; Chiu HC; Wo TY; Huang YJ; Tseng SC; Huang YC; Chen HJ; Syu JJ; Chen CY; Jian YT; Jian YJ; Lin YW
Lung Cancer; 2013 Dec; 82(3):397-406. PubMed ID: 24138903
[TBL] [Abstract][Full Text] [Related]
57. Gemigliptin ameliorates Western-diet-induced metabolic syndrome in mice.
Choi SH; Leem J; Park S; Lee CK; Park KG; Lee IK
Can J Physiol Pharmacol; 2017 Feb; 95(2):129-139. PubMed ID: 27918207
[TBL] [Abstract][Full Text] [Related]
58. Absorption, distribution, metabolism and excretion of gemigliptin, a novel dipeptidyl peptidase IV inhibitor, in rats.
Kim Y; Kim U; Kim IS; Lee SH; Lee J; Kim DH; Yoo HH
Xenobiotica; 2014 Jul; 44(7):627-34. PubMed ID: 24738939
[TBL] [Abstract][Full Text] [Related]
59. Metformin decreases IGF1-induced cell proliferation and protein synthesis through AMP-activated protein kinase in cultured bovine granulosa cells.
Tosca L; Ramé C; Chabrolle C; Tesseraud S; Dupont J
Reproduction; 2010 Feb; 139(2):409-18. PubMed ID: 19906888
[TBL] [Abstract][Full Text] [Related]
60. Treatment with metformin is associated with higher remission rate in diabetic patients with thyroid cancer.
Klubo-Gwiezdzinska J; Costello J; Patel A; Bauer A; Jensen K; Mete M; Burman KD; Wartofsky L; Vasko V
J Clin Endocrinol Metab; 2013 Aug; 98(8):3269-79. PubMed ID: 23709654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
